Our Focus
Pipeline
- CardiolRx™
- CRD-38
Clinical Trials
Company
Insights
Investors

Investor Resources

Events & Presentations
Press Releases
Analyst Coverage
Stock Information
Filings & Financials
Corporate Governance
FAQ

Contact Us

Investor Resources

Cannabidiol inhibits the mesothelial to mesenchymal transition in experimental pericarditis

No items found.

Join our newsletter

Sign up to receive the latest news from Cardiol Therapeutics!

By subscribing you agree to with our Privacy Policy

Email(Required)

Company
Our Focus
Pipeline
Insights
Investors

2023 Cardiol Therapeutics. All right reserved.